{"altmetric_id":3363888,"counts":{"readers":{"mendeley":6,"citeulike":0,"connotea":0},"total":{"posts_count":1},"wikipedia":{"unique_users_count":1,"unique_users":["en:9703026"],"posts_count":1}},"citation":{"altmetric_jid":"4f6fa4e93cf058f610002495","authors":["Daniel Kahn","J. Christopher Austin","Robert T. Maguire","Sara J. Miller","Jack Gerstbrein","Richard D. Williams"],"doi":"10.1089\/cbr.1999.14.99","endpage":"111","first_seen_on":"2015-02-05T22:07:31+00:00","issns":["1084-9785","1557-8852"],"issue":"2","journal":"Cancer Biotherapy & Radiopharmaceuticals","last_mentioned_on":1239930824,"links":["http:\/\/dx.doi.org\/10.1089\/cbr.1999.14.99"],"pubdate":"1999-04-01T00:00:00+00:00","publisher_subjects":[{"name":"Pharmacology And Pharmaceutical Sciences","scheme":"era"}],"scopus_subjects":["Life Sciences","Medicine","Health Sciences","Pharmacology, Toxicology and Pharmaceutics","Biochemistry, Genetics and Molecular Biology"],"startpage":"99","subjects":["neoplasms","radiotherapy","pharmacology"],"title":"\n              A Phase II Study of [\n              90\n              Y] Yttrium-Capromab Pendetide in the Treatment of Men with Prostate Cancer Recurrence Following Radical Prostatectomy\n            ","type":"article","volume":"14","mendeley_url":"http:\/\/www.mendeley.com\/research\/phase-ii-study-90y-yttriumcapromab-pendetide-treatment-men-prostate-cancer-recurrence-following-radi-3"},"altmetric_score":{"score":3,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":3},"context_for_score":{"all":{"total_number_of_other_articles":4864474,"mean":5.7937841570951,"rank":1186971,"this_scored_higher_than_pct":63,"this_scored_higher_than":3085602,"rank_type":"exact","sample_size":4864474,"percentile":63},"similar_age_3m":{"total_number_of_other_articles":173478,"mean":8.5854373202214,"rank":50645,"this_scored_higher_than_pct":69,"this_scored_higher_than":120554,"rank_type":"exact","sample_size":173478,"percentile":69},"this_journal":{"total_number_of_other_articles":142,"mean":2.221304964539,"rank":13,"this_scored_higher_than_pct":78,"this_scored_higher_than":112,"rank_type":"exact","sample_size":142,"percentile":78},"similar_age_this_journal_3m":{"total_number_of_other_articles":14,"mean":5.9,"rank":2,"this_scored_higher_than_pct":85,"this_scored_higher_than":12,"rank_type":"exact","sample_size":14,"percentile":85}}},"demographics":{"users":{"mendeley":{"by_status":{"Researcher":2,"Student  > Doctoral Student":1,"Student  > Ph. D. Student":2,"Student  > Bachelor":1},"by_discipline":{"Medicine and Dentistry":4,"Neuroscience":1,"Agricultural and Biological Sciences":1}}},"geo":{"mendeley":{"IT":1}}},"posts":{"wikipedia":[{"title":"Indium (111In) capromab pendetide","url":"http:\/\/en.wikipedia.org\/?diff=prev&oldid=284328642#altmetric_citation_0","license":"public","citation_ids":[3363888],"posted_on":"2009-04-17T01:13:44+00:00","summary":"Indium (111In) capromab pendetide (trade name Prostascint) is used to image the extent of prostate cancer.","page_url":"http:\/\/en.wikipedia.org\/?curid=9703026","wiki_lang":"en","author":{"name":"OMCV","url":"http:\/\/en.wikipedia.org\/wiki\/User:OMCV"}}]}}